Regeneron's Aflibercept 8mg Shows Sustained Vision Gains At Two Years
Portfolio Pulse from Vandana Singh
Regeneron Pharmaceuticals announced two-year data from the PULSAR trial investigating aflibercept 8 mg in patients with wet age-related macular degeneration. The FDA issued a Complete Response Letter for Regeneron's aflibercept 8 mg Biologics License application due to an ongoing review of inspection findings at a third-party filler. The company anticipates the FDA will take action on the aflibercept 8 mg BLA during Q3 of 2023. Regeneron's shares are up 1.00% at $793.50.
August 10, 2023 | 4:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron's two-year PULSAR trial data shows promising results. The company anticipates the FDA will take action on the aflibercept 8 mg BLA during Q3 of 2023. Regeneron's shares are up 1.00%.
The positive results from the PULSAR trial and the anticipated FDA action on the company's Biologics License application could potentially boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100